Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 1/2012

01.02.2012 | Adis Profile Report

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]

Profile Report

verfasst von: Sean T. Duggan

Erschienen in: Pediatric Drugs | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

Invasive pneumococcal disease (IPD) is caused by Streptococcus pneumoniae (pneumococcus), a Gram-positive encapsulated diplococcus, and remains a leading cause of morbidity and mortality in children below the age of 5 years.[1] It accounts for ≈11% of all deaths in this age group throughout the world,[1] with children in developing countries at particular risk.[1‐3] The clinical presentations of IPD include bacteremia, bacteremic pneumonia, and meningitis, while the most common noninvasive manifestations are acute otitis media (AOM) and pneumonia.[2] …
Literatur
1.
O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009 Sep 12; 374(9693): 893–902PubMedCrossRef
2.
3.
4.
Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000 Jan; 30(1): 100–21PubMedCrossRef
5.
Henrichsen J. Typing of Streptococcus pneumoniae: past, present, and future. Am J Med 1999 Jul 26; 107(1A): 50–54SCrossRef
6.
Ardanuy C, Fenoll A, Rolo D, et al. Characterization of serotype 5 pneumococci causing an outbreak of invasive pneumococcal disease (IPD) in 2005 in Barcelona, Spain. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25–28; Washington, DC
7.
Cohen R, Levy C, de La Rocque F, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006 Nov;25(11): 1001–7PubMedCrossRef
8.
Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003 May 1; 348(18): 1737–46PubMedCrossRef
9.
Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among un vaccinated household members. Clin Infect Dis 2008 Oct 15; 47(8): 989–96PubMedCrossRef
10.
Isaacman DJ, Fletcher MA, Fritzell B, et al. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). Vaccine 2007 Mar 22; 25(13): 2420–7PubMedCrossRef
11.
Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 2007 Nov 1; 196(9): 1346–54PubMedCrossRef
12.
Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009 Jan 15; 360(3): 244–56PubMedCrossRef
13.
Nuorti P, Rosen J, Thomas A. Invasive pneumococcal disease in young children caused by serotypes in the new 13-valent conjugate vaccine: implications for immunization strategies [abstract no. G1-1554]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12–15; San Francisco (CA)
14.
Black S. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Pediatr Infect Dis J 2010 Apr; 29(4): 301–3PubMed
15.
O’Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 2003 May 16; 21(17–18): 1815–25PubMedCrossRef
16.
17.
18.
Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®]. Drugs 2010 Oct; 70(15): 1973–86PubMedCrossRef
19.
Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 3-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17(6): 1017–26PubMedCrossRef
20.
Martinon-Torres F, Gimenez-Sanchez F, Gurtman A, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given with meningococcal C tetanus toxoid conjugate and other routine pediatric vaccinations [poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4–8; Nice
21.
Diez-Domingo J, Gurtman A, Bernaola E, et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers receiving routine vaccinations in Spain. 27 th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2009 Jun 9–13; Brussels
22.
Hughes JY, Snape CL, Klinger CL, et al. Immunogenicity of booster doses of 13-valent pneumococcal conjugate and HIB/MENC vaccines given at12 months of age in the UK. 27 th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2009 Jun 9–13; Brussels
23.
Klinger CL, Snape MD, John T, et al. Immunogenicity of DTaP-IPV-Hib and menC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine [abstract no. GI-2118]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America; a joint meeting; 2008 Oct 25–28; Washington, DC: 367
24.
Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability and immunologic noninferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010; 28(25): 4192–203PubMedCrossRef
25.
Gadzinowski J, Tansey S, Mellelieu T, et al. A phase 3 trial evaluating the safety, tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate vaccine [abstract no. GI-2116]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America: a joint meeting; 2008 Oct 25–28; Washington, DC
26.
Grimprel E, Laudat F, Baker SA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccination to healthy children in France. 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2009 Jun 9–13; Brussels
27.
Grimprel E, Scott D, Laudat F, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vacination to healthy infants in France [abstract no. GI-2119]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America: a joint meeting; 2008 Oct 25–28; Washington, DC
28.
Gadzinowski J, Daniels E, Scott DA, et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine with/without polysorbate 80 in healthy infants in Poland. 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2009 Jun 9–13; Brussels
29.
Silfverdal AV, Tansey SP, Skoglund G, et al. Phase 3, open-label trial of 13-valent pneumococcal conjugate vaccine as a toddler dose in healthy children previously partially immunized with 7-valent pneumococcal conjugate vaccine [poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4–8; Nice
30.
Wysocki J, Daniels ED, Sarkozy DA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naive to previous vaccination. 27 th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2009 Jun 9–13; Brussels
Metadaten
Titel
Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]
Profile Report
verfasst von
Sean T. Duggan
Publikationsdatum
01.02.2012
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 1/2012
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/11207010-000000000-00000

Weitere Artikel der Ausgabe 1/2012

Pediatric Drugs 1/2012 Zur Ausgabe

Adis Drug Profile

Everolimus

Original Research Article

Drug Exposure and Pregnancy Outcome in Mozambique

Adis Profile Report

Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®)

Therapy In Practice

Anesthetic-Related Neurotoxicity and the Developing Brain

Adis Profile Report

Candesartan Cilexetil in Children and Adolescents Aged 1 to <17 Years with Hypertension

Review Article

Celiac Disease in Pediatric Patients with Autoimmune Hepatitis

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise